We should be aware this application isn't that new, 2022 published 23.
It however reinforced my view that MAP scores will be used both as a indication for treatment and a measure of efficacy.
@reginaldp , "The golden egg " The data. The treatment is a life saver. Long term survival odds is why immune transplants are reserved for last resort use . Imagine how big the market for aGVHD would be if say 10% of MS and IBD patients decided that aGVHD was no longer the issue with a immune transplant. As outcomes become better the market will grow.
We should be aware this application isn't that new, 2022...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |